Prolonged deferral of antiretroviral therapy in the SAPIT trial: did we need a clinical trial to tell us that this would increase mortality?
Boulle
Andrew
A
School of Public Health and Family Medicine, University of Cape Town.
Clayden
Polly
P
Cohen
Karen
K
Cohen
Ted
T
Conradie
Francesca
F
Dong
Krista
K
Geffen
Nathan
N
Grimwood
Ashraf
A
Hurtado
Rocio
R
Kenyon
Christopher
C
Lawn
Stephen
S
Maartens
Gary
G
Meintjes
Graeme
G
Mendelson
Marc
M
Murray
Megan
M
Rangaka
Molebogeng
M
Sanne
Ian
I
Spencer
David
D
Taljaard
Jantjie
J
Variava
Ebrahim
E
Venter
W D Francois
WD
Wilson
Douglas
D
D017088:AIDS-Related Opportunistic Infections / Q000382:microbiology; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D044966:Anti-Retroviral Agents / Q000008:administration & dosage*; D018791:CD4 Lymphocyte Count; D002986:Clinical Trials as Topic / Q000941:ethics*; D004334:Drug Administration Schedule; D015658:HIV Infections / Q000188:drug therapy* / Q000401:mortality*; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome; D013019:South Africa / Q000453:epidemiology; D057212:Therapeutic Equipoise; D014376:Tuberculosis / Q000188:drug therapy* / Q000401:mortality
D000900:Anti-Bacterial Agents; D044966:Anti-Retroviral Agents